J Gastroenterol Hepatol Endosc | Volume 6, Issue 3 | Research Article | Open Access
Shoaib Ahmed Khan, Raja Taha Yaseen Khan*, Zain Majid, Muhammad Ali Khalid, Farina M Hanif, Syed Mudassir Laeeq, Nasir Hasan Luck, Husnain Ali Metlo, Kiran Bajaj and Muhammad Adeel
Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Pakistan
*Correspondance to: Raja Taha Yaseen Khan
Fulltext PDFIntroduction: Measurement of patient’s Health Related Quality of Life (HRQOL) is acquiring attention in medical research, as it used to gauge the influence of a long-lasting disease or surgery on patients’ health. It has now become the principal goal of medical care and is a subjective multidimensional concept. In past, the treatment with Pegylated Interferon (PEG-IFN) had a negative impact on quality of life leading to lower treatment adherence. Therefore, we aim to evaluate satisfactory quality of life with Direct Acting Antiviral Agents (DAAs). The result of this study not only shed light on impact of DAAs on HRQOL but also helps physician assessment regarding prescribing these expensive medications.
Objective: To determine the frequency of satisfactory quality of life assessed on CLDQ in chronic hepatitis C patients treated with direct oral antiviral agents.
Setting: Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation Karachi (SIUT).
Duration: 6 months from October 2018 to March 2019.
Design: Longitudinal study.
Subject and Methods: A total of 168 Patient diagnosed as hepatitis C for last 6 months and has not been treated for HCV were included in this study. CLDQ score (Appendix-A). Data was collected and was transferred to pre-designed Performa. Mean score of >5 was associated with satisfactory HRQOL.
Results: Majority of patients were female 92 (54.76%) with average age of 44.58 ±10.69 years. Satisfactory quality of life was observed in 76.79% (129/168) in one month after completion of treatment. One-month post-treatment with direct oral antiviral agents, there was significant increase in mean CLDQ score (3.5 ± 1.16 vs. 5.4 ±1.76; p=0.0005 paired t-test applied).
Conclusion: This study revealed short-term positive impact on the HRQoL of the patients with chronic hepatitis C treated with sofosbuvir based direct acting antiviral agents.
Chronic hepatitis C; CLDQ; Direct oral antiviral agents; Satisfactory quality of life; PEG-IFN
Khan SA, Khan RTY, Majid Z, Khalid MA, Hanif FM, Laeeq SM, et al. Impact on Health-Related Quality of Life (HRQOL) Using Direct Antiviral Agents (DAA) in Patients with Chronic Hepatitis C. J Gastroenterol Hepatol Endosc.2021; 6(3): 1102..